Eli Lilly and Company announced data demonstrating more patients ... as an oral presentation at United European Gastroenterology (UEG) Week, held in Vienna, Austria from October 12-15. Mirikizumab is ...

Eli Lilly announced data demonstrating more patients ... Week, held in Vienna, Austria from October 12-15. Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

EU mid-market update: Complex tapestry of macro themes sees Germany avert recession with stubborn CPI, an imminent UK budget, ...

Austria on 7 th –11 th September 2024. Funk has received scientific grants, congress invitations, or speaker/consultant fees from Amgen, Astra Zeneca, Bristol Myers Squibb, Boehringer Ingelheim, ...

Conditions are getting a bit more challenging for the drugmaker.

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...